Management of Occupational and Nonoccupational HIV Exposure
Summary
- Combination of tenofovir plus emtricitabine recommended as preferred backbone of a 3-drug regimen by USPHS and CDC guidelines[USPHS 2013; CDC 2016]
- WHO guidelines also list tenofovir DF plus lamivudine as a preferred NRTI backbone[WHO 2014]
- INSTIs and PIs are preferred companions to dual-NRTI backbone in PEP[CDC 2016; USPHS 2013]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content